Current State of Type 1 Diabetes Immunotherapy: Incremental Advances, Huge Leaps, or More of the Same?
Thus far, none of the preclinically successful and promising immunomodulatory agents for type 1 diabetes mellitus (T1DM) has conferred stable, long-term insulin independence to diabetic patients. The majority of these immunomodulators are humanised antibodies that target immune cells or cytokines. T...
Saved in:
Main Authors: | Brett Phillips, Massimo Trucco, Nick Giannoukakis |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2011/432016 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Third Leap Zagreb Index for Trees
by: Jia-Ming Zhu, et al.
Published: (2019-01-01) -
Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
by: Yingjun Xie, et al.
Published: (2018-01-01) -
Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances
by: Merve Kulbay, et al.
Published: (2025-01-01) -
Huge Pyogenic Granuloma of the Penis
by: Fatih Akbulut, et al.
Published: (2015-01-01) -
Huge Pulmonary Artery Aneurysm
by: Aiman M Hammad, et al.
Published: (2009-01-01)